Blockbuster weight-loss drugs, and a stomach that stopped working.
GLP-1 receptor agonists have been linked to delayed gastric emptying and gastroparesis in a subset of long-term users.
- 10,000
- Claims filed
- Litigation ongoing
- Recovered to date
- 1
- Studies cited
Quick eligibility check
Step 1 of 3
Were you exposed to or treated with this product?
Confidential. No fee unless compensation is recovered.
Overview
Semaglutide-based medications have driven a transformation in diabetes and obesity treatment. A growing number of users report severe gastric complications, and courts are examining whether the manufacturers adequately warned of the risk of gastroparesis and related conditions.
Who may qualify
- Prescribed and used Ozempic, Wegovy, Rybelsus, or another semaglutide product
- Diagnosis of gastroparesis, ileus, or bowel obstruction — or hospitalization for persistent vomiting
- Medical records connecting the diagnosis to the period of use
- Filing within your state's limitations period
Documented injuries & conditions
Medical studies & evidence
GLP-1 Use and Gastroparesis Diagnosis
Mayo Clinic · 2024
Litigation updates
2026-05-02
Label update and MDL consolidation
The FDA has updated labeling to describe ileus risk, and federal litigation is consolidated in the Eastern District of Pennsylvania.
Frequently asked questions
Reported cases include severe gastroparesis, ileus, and intestinal obstruction — some requiring hospitalization — beyond the nausea listed on the label.
Your Ozempic & GLP-1 Gastroparesis claim may still be viable.
Limitations periods vary by state and by claim type. A three-minute review confirms whether your file is still within the filing window.